NEW YORK (GenomeWeb) – Molecular diagnostics firm IntegraGen announced that it is collaborating with the French Intergroup of Thoracic Oncology (IFCT), a network of lung cancer specialists, to investigate the potential of a specific microRNA as a biomarker for advanced non-small cell lung cancer.

Specifically, the partners will examine whether the expression of the miRNA, miR-31-3p, is correlated with patient outcomes associated with epidermal growth factor receptor (EGFR)-targeted therapies for lepidic adenocarcinomas of the lung.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.